Pharmacyte Biotech Inc (OTCMKTS:PMCB) has been moving up steadily in recent trading since reversing off $0.0277 lows. PMCB has a long history of big moves trading as high as $0.60 in 2014 and is an Investors favorite with a large and faithful shareholder base.
PMCB stared trading on the OTCBB on January 8 of this year after the name change from Nuvilex, Inc. The ticker symbol changed from NVLX to PMCB.
Pharmacyte Biotech Inc (OTCMKTS:PMCB) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon their unique, proprietary and patented cellulose-based live cell encapsulation technology known as Cell-in-a-Box®.
PMCB has been around for years and was initially incorporated as eFoodSafety.com, Inc. in 1996 in Nevada. The recent move up comes after PMCB outlined 2016 milestones as it advances its new treatment for pancreatic cancer into the clinic in the United States with study sites in Europe and Australia.
The live-cell encapsulation technology employed by Pharmacyte Biotech is a way to enclose living cells in protective “cocoons” about the size of the head of a pin. Each capsule can enclose approximately 10,000 cells and the technology is considered a “platform” upon which treatments can be developed.
Dr.Mark Rabe, chairman of the advisory board of Pharmacyte Biotech subsidiary, Medical Marijuana Sciences (MMS) summed it up perfectly when he said ”The live cell encapsulation platform employed by Nuvilex is a unique patented technology on which treatments can be developed for deadly and debilitating diseases such as cancer and diabetes. The technology has shown to be successful in the treatment of pancreatic cancer in initial clinical trials using the conventional chemotherapy drug ifosphamide. ”
To get a sense of just how valuable this technology could be, consider a recent report published by U.S. based market research company, Transparency Market Research “ the global diabetes devices and drugs market was valued at USD 54.04 billion in 2012 and is estimated to reach a market worth of USD 83.0 billion in 2019 growing at a CAGR of 5.9% from 2013 to 2019.
Many investors in the Company view Pharmacyte Biotech Cell-in-a-Box® cell encapsulation technology as THE future of diabetes treatment and suggest the Company is a prime buy out candidate from a major such as Bayer who may be closely watching PMCB.
To Find out the inside Scoop on PMCB Subscribe to Microcapdaily.com Right Now by entering your Email in the box below


PMCB stared trading on the OTCBB on January 8 after the name change from Nuvilex, Inc. The ticker symbol changed from NVLX to PMCB. The Company said that the name change is part of its transformation process to operate solely as a pure biotechnology firm leveraging its Cell-in-a-Box®
The stock has benefited from the pot connection; the sector is heating up again big time with a recent report from MMJ Business Daily suggesting that 2015 is expected not only to see more investment dollars flow into the market but it could even outpace the growth rate seen in 2014. States like Nevada, Illinois, Massachusetts, Oregon, and Alaska have all been identified as industry drivers this year. Furthermore, the rise in “big money” from some major investment funds has just started to hit the sector.
PMCB landed a leading figure in the medical marijuana field in Dr. Mark L. Rabe who was appointed as the Chairman of the Scientific Advisory Board of Medical Marijuana Sciences (MMS).
In fact Pharmacyte Biotech has been very successful in attracting top talent to the Company including their COO Dr. Crabtree who used to work at Bristol Meyers and successfully managed the project that achieved FDA approval for Taxol. Another huge asset is their Chief Scientific Officer ; Dr. Robert F. Ryan an expert in helping small companies in bringing their products to market through the rigorous FDA approval process.
On September 15 PMCB addressed shareholders on the development of PharmaCyte’s therapy for advanced pancreatic cancer.
The Chief Executive Officer of PharmaCyte, Kenneth L. Waggoner, commented, “We understand that shareholders are frustrated with our current share price; however, the share price doesn’t reflect where PharmaCyte is today. In what has been a relatively short time for a biotech company, we have dramatically moved our Cell-in-a-Box [(R)] technology forward along the path toward the clinic, we have surrounded our technology with some of the best minds in the industry and we have put together a team that is working diligently every single day to get PharmaCyte in front of the U.S. Food and Drug Administration (FDA) so that we can clear the final hurdles that will allow us to begin our clinical trial in advanced pancreatic cancer. There are numerous moving parts on many fronts. Just because our shareholders aren’t seeing news on a weekly basis, this does not mean there isn’t a flurry of work being done every single day.
“It is important for our shareholders to realize that PharmaCyte’s pancreatic cancer therapy is classified by drug regulatory authorities as a ‘biologic’ rather than a single molecule drug or a New Chemical Entity (NCE). This is because our therapy involves the use of living, genetically altered human cells. The overall development process is much more involved and more complex for a biologic than an NCE. Nevertheless, PharmaCyte’s therapy is moving forward at a realistic pace. Our partner Austrianova will be carrying out an engineering manufacturing ‘run’ in the near future of the production of the capsules that will be used with low dose ifosfamide as our pancreatic cancer therapy. If successful, not only will this run define the specifications of the capsules that will be use to encapsulate the living cells, it will also set the stage for cGMP production of the capsules for our planned clinical trial.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $33 million market valuation PMCB has $2.4 million in the treasury, no revenues to date and fast rising shot term debt. But PMCB is an exciting story developing in small caps; not only does PMCB have a history of explosive moves the stock has a loyal shareholder base who believes this one moves much higher. The Company has made some huge steps recently towards accelerated FDA approval for its pancreatic cancer treatment using Phase 2b data that outperformed Eli Lilly’s Gemzar in prior trials; according to available information the Cell-In-The-Box technology beats the current Gold Standard on The market, and we are talking about a market worth billions. We will be updating on PMCB when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with PMCB.
Disclosure: we hold no position in PMCB either long or short and we have not been compensated for this article.